Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The double-blind, international trial enrolled 37